Journal
CELL REPORTS MEDICINE
Volume 3, Issue 10, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.xcrm.2022.100783
Keywords
-
Categories
Funding
- European Research Council (ERC) under the European Union [694502, 875102 -MInfla-Tilc]
- Agence Nationale de la Recherche including the PIONEER Project [ANR-17-RHUS-0007]
- MSDAvenir
- Innate Pharma
Ask authors/readers for more resources
This study presents the design of tetraspecific molecules that can activate natural killer cells for cancer therapy. The tetraspecific molecules selectively activate and proliferate natural killer cells, and the binding to tumor-associated antigens triggers cell cytotoxicity and cytokine production. In animal experiments, the tetraspecific molecules control tumor growth and accumulate at the tumor site. Furthermore, they can deplete circulating B cells without causing toxicity in non-human primates.
Harnessing innate immunity is emerging as a promising therapeutic approach in cancer. We report here the design of tetraspecific molecules engaging natural killer (NK) cell-activating receptors NKp46 and CD16a, the beta-chain of the interleukin-2 receptor (IL-2R), and a tumor-associated antigen (TAA). In vitro, these tetraspecific antibody-based natural killer cell engager therapeutics (ANKETs) induce a preferential activation and proliferation of NK cells, and the binding to the targeted TAA triggers NK cell cytotoxicity and cytokine and chemokine production. In vivo, tetraspecific ANKETs induce NK cell proliferation and their accumulation at the tumor bed, as well as the control of local and disseminated tumors. Treatment of non-human primates with CD20-directed tetraspecific ANKET leads to CD20(+) circulating B cell depletion, with minimal systemic cytokine release and no sign of toxicity. Tetraspecific ANKETs, thus, constitute a technological platform for harnessing NK cells as next-generation cancer immunotherapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available